Company: HROW
Filing Date: 2025-05-08
Form Type: 10-Q
Source: 0001641172-25-009263
Chunk: 59

Company: HARROW, INC.
Filing Date: 2025-05-08
Form: 10-Q
Item: Item 2
Chunk 59
---
 implied by such forward-looking statements. Risks that could cause actual results to differ from those
expressed or implied by the forward-looking statements we make include, among others, risks related to: liquidity or results of
operations; our ability to successfully implement our business plan, develop and commercialize our products, product candidates and
proprietary formulations in a timely manner or at all, identify and acquire additional products, manage our pharmacy operations,
refinance and otherwise service our debt, obtain financing necessary to operate our business, recruit and retain qualified
personnel, manage any growth we may experience and successfully realize the benefits of our previous acquisitions and any other
acquisitions and collaborative arrangements we may pursue; the ongoing communications with the U.S. Food and Drug Administration
relating to compliance and quality plans at our outsourcing facility in New Jersey; competition from pharmaceutical companies,
outsourcing facilities and pharmacies; general economic and business conditions, including inflation and supply chain challenges;
regulatory and legal risks and uncertainties related to our pharmacy operations and the pharmacy and pharmaceutical business in
general; physician interest in and market acceptance of our current and any future formulations and compounding pharmacies
generally; and the other risks and uncertainties described under the heading “Risk Factors” in Part II, Item 1A of this
Quarterly Report and in our other filings with the SEC. You should not place undue reliance on forward-looking statements.
Forward-looking statements speak only as of the date they are made and, except as required by law, we undertake no obligation to
revise or publicly update any forward-looking statement for any reason.

Overview

We
are a leading eyecare pharmaceutical company engaged in the discovery, development, and commercialization of innovative ophthalmic
pharmaceutical products for the U.S. market. We help U.S. eyecare professionals preserve the gift of sight by making our
comprehensive portfolio of prescription and non-prescription pharmaceutical products accessible and affordable to millions of
Americans each year. We own commercial rights to one of the largest portfolios of branded ophthalmic pharmaceutical products in
North America, all of which are marketed under the Harrow name. We also own and operate ImprimisRx, one of the nation’s
leading ophthalmology-focused pharmaceutical-compounding businesses.

Factors Affecting Our Performance

We believe the primary factors
affecting our performance are our ability to increase revenues of our branded pharmaceutical products, proprietary compounded formulations
and certain non-proprietary products, grow and gain operating efficiencies in our operations, avoid